| abstract |
The present invention relates to polynucleotides for use in cancer therapy. In particular, the invention provides a polynucleotide capable of expressing an epilope-β 2 m fusion protein; for use in the generation of cytotoxic T lymphocyte (CTL) responses against a tumour, and a polynucleotide capable of expressing an epitope-β 2 m fusion protein; for use in a method of restoring antigen presentation in the tumour of a host. |